Relapse to prior therapy is the most important factor for the retreatment response in patients with chronic hepatitis C virus infection
- PMID: 17696934
- DOI: 10.1111/j.1478-3231.2007.01508.x
Relapse to prior therapy is the most important factor for the retreatment response in patients with chronic hepatitis C virus infection
Abstract
Background: Treatment options for hepatitis C have developed rapidly in the past decade. The current treatment of choice is a combination of pegylated-interferon-alpha (PEG-IFN-alpha) and ribavirin. With the development of more therapy options, patients who failed in prior therapy hope to clear hepatitis C virus by undergoing a more effective retreatment regime. In this report, we investigated response rates to combination therapy [standard IFN-alpha or PEG-IFN-alpha and ribavirin] in patients who relapsed or failed in prior therapy.
Methods: Ninety-three patients were included in this retrospective study. All patients failed to previous IFN-alpha monotherapy (n=55) or to a combination of standard IFN-alpha and ribavirin (n=38). Fifty-nine patients were nonresponders and 34 were relapsers. Thirty-five patients were retreated with standard IFN-alpha plus ribavirin and 58 received PEG-IFN-alpha combination therapy.
Results: Sustained virologic response (SVR) was induced in 31% of all patients. The highest SVR rate (58%) was observed in relapsers to standard IFN-alpha combination therapy who were retreated with PEG-IFN-alpha combination therapy. The SVR rate in relapsers to standard IFN-alpha monotherapy who received a standard IFN-alpha combination therapy was 50%. Relapsers responded in a significantly higher proportion to retreatment than nonresponders (56% vs. 17%, P<0.001). Relapse to previous therapy was identified as an independent predictor for therapy response. The lowest SVR rate was observed in nonresponders to standard IFN-alpha combination therapy who were retreated with PEG-IFN-alpha combination therapy (1/26; 4%).
Conclusions: In relapsers, retreatment with the most effective therapy regime to date a combination of PEG-IFN-alpha and ribavirin, is promising. However, retreatment with PEG-IFN-alpha combination therapy in nonresponders to standard IFN combination therapy is not effective.
Similar articles
-
Meta-analysis: re-treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy.Aliment Pharmacol Ther. 2010 Oct;32(8):969-83. doi: 10.1111/j.1365-2036.2010.04427.x. Epub 2010 Aug 15. Aliment Pharmacol Ther. 2010. PMID: 20937042
-
Retreatment with peginterferon α-2a + ribavirin in patients who failed previous peginterferon α-2b + ribavirin combination therapy.Dig Dis. 2012;30(6):554-60. doi: 10.1159/000343064. Epub 2012 Dec 13. Dig Dis. 2012. PMID: 23258094
-
Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients.Gastroenterology. 2006 Apr;130(4):1098-106. doi: 10.1053/j.gastro.2006.02.016. Gastroenterology. 2006. PMID: 16618404 Clinical Trial.
-
Clinical trial results of peginterferons in combination with ribavirin.Semin Liver Dis. 2003;23 Suppl 1:35-46. doi: 10.1055/s-2003-41633. Semin Liver Dis. 2003. PMID: 12934167 Review.
-
Treatment of chronic hepatitis C in southern Taiwan.Intervirology. 2006;49(1-2):99-106. doi: 10.1159/000087271. Intervirology. 2006. PMID: 16166797 Review.
Cited by
-
Impact of ribavirin dose on retreatment of chronic hepatitis C patients.World J Gastroenterol. 2012 Jun 21;18(23):2966-72. doi: 10.3748/wjg.v18.i23.2966. World J Gastroenterol. 2012. PMID: 22736920 Free PMC article.
-
KASL clinical practice guidelines: management of hepatitis C.Clin Mol Hepatol. 2016 Mar;22(1):76-139. doi: 10.3350/cmh.2016.22.1.76. Epub 2016 Mar 28. Clin Mol Hepatol. 2016. PMID: 27044763 Free PMC article. Review. No abstract available.
-
KASL clinical practice guidelines: management of hepatitis C.Clin Mol Hepatol. 2014 Jun;20(2):89-136. doi: 10.3350/cmh.2014.20.2.89. Epub 2014 Jun 30. Clin Mol Hepatol. 2014. PMID: 25032178 Free PMC article. No abstract available.
-
Expert opinion on the treatment of patients with chronic hepatitis C.J Viral Hepat. 2009 Feb;16(2):75-90. doi: 10.1111/j.1365-2893.2008.01012.x. Epub 2008 Aug 28. J Viral Hepat. 2009. PMID: 18761607 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous